BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
April 21, 2010
View Archived Issues
FIBREX Medical discloses novel cell adhesion inhibitors
Read More
Roche discovers novel NS5B inhibitors for HCV infection
Read More
Abbott describes new indole and indoline derivatives with neurotrophic activity
Read More
NeuroSearch identifies novel potassium channel modulators
Read More
Biotechnology Research claims new PGE2, NMDA and MC receptor antagonists
Read More
Data on vipadenant warrant further development in moderate- to late-stage PD patients
Read More
Quinacrine does not extend survival in sporadic Creutzfeldt-Jakob disease
Read More
Ongoing tacrolimus treatment beneficial for atopic dermatitis
Read More
ONO-8539 for overactive bladder well tolerated in healthy adults
Read More
Decline of mGlu5 receptor binding as a marker of early Alzheimer's disease
Read More
First phase III trial of ThromboGenics' microplasmin for eye disease meets primary endpoint
Read More
Topline phase III data disclosed on Benlysta in systemic lupus erythematosus
Read More
QLT reports interim phase Ib data on QLT-091001 in Leber's congenital amaurosis
Read More
Roche advances RG-7348 for hepatitis C into the clinic
Read More
LCL-161 well tolerated in ongoing first-in-human study
Read More
SCH-900776 sensitizes cancer cells to hydroxyurea and gemcitabine
Read More
Gilead provides update on development of fixed-dose Truvada/TMC-278 regimen for HIV
Read More
Cornerstone receives FDA clearance for phase I trial of CPI-613 in hematologic malignancies
Read More
Cadence Pharmaceuticals to resubmit NDA for Ofirmev injection
Read More
EntreMed completes registered direct offering to fund clinical development of ENMD-2076
Read More
Acorda plans phase I trial of GGF2 for treatment of heart failure
Read More
European Joulferon MAA for chronic hepatitis C withdrawn
Read More
Southern Research and Vivo Biosciences sign promotion and comarketing agreement
Read More
ChromoCure and GRG sign letter of intent in merger and acquisition agreement
Read More
Elan considers dividing Elan Drug Technologies into two companies
Read More
Abbott completes tender offer to finalize acquisition of Facet Biotech
Read More